SEC EDGAR · Company announcement
TNDM: Leadership change
Filed 8-K for an event or period dated 2026-05-20. Leadership change.
Follow TNDM- Became public
- May 21, 2026, 4:10 PM EDT
- Event / period date
- May 20, 2026
- Collected
- Nov 10, 2026, 2:16 PM EST
Why this is connected
This filing identifies TANDEM DIABETES CARE INC as the issuer of the security. The company's SEC identifier connects it to TNDM.
Source evidence
Read the source excerpt or record
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. At the Annual Meeting, the Company’s stockholders also approved the Company’s 2023 Long-Term Incentive Plan, as amended, to, among other things, increase the number of shares of the Company’s common stock (Common Stock) authorized for issuance under the plan by 3,260,000 shares (as so amended, the Amended Plan). The Amended Plan was previously approved by the Board, subject to stockholder approval at the Annual Meeting. A description of the Amended Plan is set forth in the Proxy Statement in the section titled “Proposal 3: 2023 Long-Term Incentive Plan.” The description of the Amended Plan contained herein and in the Proxy Statement are qualified in their entirety by reference to the Amended Plan, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference. Item 5.07 Submission of Matters to a Vote of Security Holders . On May 20, 2026, the Company held the Annual Meeting. There were 68,504,233 shares of Common Stock outstanding on March 23, 2026, the record date for the Annual Meeting, and 57,964,375 shares of Common Stock were present virtually or represented by proxy at the Annual Meeting. The following tables set forth the final results of the voting for the matters voted upon at the Annual Meeting. These matters are described in more detail in the Proxy Statement. Proposal 1 : To elect nine directors for a one-year term expiring at the 2027 annual meeting of stockholders. The stockholders elected nine directors by the following votes: Name of Director For Against Abstain Broker Non-Votes Rebecca Robertson 54,160,282 799,310 25,702 2,979,081 Sandra Beaver 54,607,191 348,050 30,053 2,9
Congressional trading in TNDM
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Oct 12, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Bought Tandem Diabetes Care TNDM
$1K–$15K · Traded Sep 29, 2026 · disclosed Oct 12, 2026
- Apr 7, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Bought Tandem Diabetes Care TNDM
$1K–$15K · Traded Mar 3, 2026 · disclosed Apr 7, 2026
- Oct 15, 2025$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Bought Tandem Diabetes Care TNDM
$1K–$15K · Traded Sep 22, 2025 · disclosed Oct 15, 2025 · Joint
- Apr 10, 2025$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Sold Tandem Diabetes Care TNDM
$1K–$15K · Traded Mar 19, 2025 · disclosed Apr 10, 2025 · Joint
- Apr 7, 2025$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Bought Tandem Diabetes Care TNDM
$1K–$15K · Traded Mar 4, 2025 · disclosed Apr 7, 2025
- Sep 11, 2024$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Bought Tandem Diabetes Care TNDM
$1K–$15K · Traded Aug 5, 2024 · disclosed Sep 11, 2024 · Joint
- Aug 13, 2023$1K–$15K
Rep. Daniel S. Goldman (D-NY-10)
Sold Tandem Diabetes Care TNDM
$1K–$15K · Traded Jul 12, 2023 · disclosed Aug 13, 2023
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.